Daewoong Pharmaceutical Holds 'Investor R&D Day'

Daewoong Pharmaceutical Holds 'Investor R&D Day'.

[Asia Economy Reporter Lee Gwan-joo] Daewoong Pharmaceutical announced on the 24th that it held an 'Investor R&D Day' at Park One in Yeouido, Seoul, introducing its global business achievements, R&D capabilities, and strategies to major institutional investors.

Seungho Jeon, CEO of Daewoong Pharmaceutical, presented the current status of global expansion and future business strategies for the botulinum toxin product Nabota and the gastroesophageal reflux disease treatment Pexuclu under the theme of 'Leap to a Global Pharmaceutical Company Based on R&D Innovation.' He emphasized that the company aims to become a global pharmaceutical company through differentiated global business strategies and open collaboration.

Additionally, Junseok Park, Head of Daewoong Pharmaceutical's New Drug Center, introduced the latest R&D pipeline including the PRS inhibitor DWN12088 under development as a treatment for pulmonary fibrosis, cell and gene therapies, the status and strategies for developing innovative blockbuster drugs, and open collaboration activities under the theme of 'Daewoong Pharmaceutical New Drugs and R&D Frontier.'

CEO Jeon stated, “We are pleased to meet market expectations through continuous new drug investments and achievements such as the new drug approval and technology export of Pexuclu tablets, as well as the overseas sales growth and market expansion of Nabota,” adding, “Daewoong Pharmaceutical will continue to do its best to enhance shareholder value.”

This content was produced with the assistance of AI translation services.